WellMarkerBio Co., Ltd. is the first spin off company
from Asan Medical Center developing patient-oriented
anticancer drug based on precision medicine.
Our Company has developed a biomarker-based cancer drugs based on
accumulated developmental experience and know-how. We have a new drug
development institute including synthetic and bio-research and
management support center.
Utilizing R&D infrastructure from Asan Medical Center in Seoul Republic of
Korea we are focusing on developing new drugs that overcome resistance of
existing therapeutic approaches.
Additionally we are focusing on developing first-in-class biomarker-based drugs
for medical unmet needs in various cancers such as colon cancer, lung
cancer and liver cancer.
We are trying to provide patients with optimized treatment through development,
validation, and efficacy analysis of predictive biomarker which is based on
actual patient clinical Information.
(05855) 7F, 155
Songpadae-ro Songpa-gu, Seoul, Korea